Akcie Agilent Technologies během pondělního obchodování dosáhly nového 52týdenního maxima 174,77 USD. Analytici zároveň zvýšili cílové ceny a konsenzus je nyní „Moderate Buy“.
Shares of Agilent Technologies, Inc. (NYSE:A – Get Free Report) hit a new 52-week high during mid-day trading on Monday. The company traded as high as $174.77 and last traded at $174.67, with a volume of 488742 shares. The stock had previously closed at $172.79.
Wall Street Analysts Forecast Growth A number of brokerages recently weighed in on A. UBS Group initiated coverage on shares of Agilent Technologies in a report on Wednesday, September 9th. They issued a “neutral” rating and a $165.00 price target for the company. TD Cowen upped their price objective on Agilent Technologies from $155.00 to $180.00 and gave the stock a “buy” rating in a report on Thursday, August 27th. Citigroup increased their price objective on Agilent Technologies from $185.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, August 27th. The Goldman Sachs Group lifted their target price on Agilent Technologies from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 27th. Finally, Bank of America boosted their target price on Agilent Technologies from $155.00 to $180.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $170.33.
Read Our Latest Report on A
Agilent Technologies Stock Down 0.1% The firm’s 50-day simple moving average is $150.90 and its 200 day simple moving average is $132.35. The company has a market cap of $49.37 billion, a P/E ratio of 34.47, a PEG ratio of 2.67 and a beta of 1.24. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.56 and a current ratio of 2.05. Agilent Technologies (NYSE:A – Get Free Report) last posted its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.13. Agilent Technologies had a return on equity of 24.45% and a net margin of 19.53%.The company had revenue of $1.88 billion for the quarter, compared to the consensus estimate of $1.84 billion. During the same quarter in the prior year, the business posted $1.37 EPS. The firm’s quarterly revenue was up 8.1% on a year-over-year basis. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, research analysts forecast that Agilent Technologies, Inc. will post 6.2 earnings per share for the current fiscal year.
Agilent Technologies Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 28th. Shareholders of record on Tuesday, October 6th will be issued a dividend of $0.2550 per share. The ex-dividend date is Tuesday, October 6th. This represents a $1.02 dividend on an annualized basis and a yield of 0.6%. Agilent Technologies’s dividend payout ratio (DPR) is 20.08%.
Insider Transactions at Agilent Technologies In other news, Director Mikael Dolsten sold 634 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $151.38, for a total transaction of $95,974.92. Following the completion of the transaction, the director directly owned 4,924 shares in the company, valued at approximately $745,395.12. The trade was a 11.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.17% of the company’s stock.
Institutional Inflows and Outflows Institutional investors have recently bought and sold shares of the company. SHP Wealth Management acquired a new stake in Agilent Technologies in the fourth quarter worth $26,000. Cedar Mountain Advisors LLC acquired a new position in shares of Agilent Technologies in the 1st quarter valued at $27,000. Markowski Investments bought a new stake in shares of Agilent Technologies in the 2nd quarter valued at $27,000. MV Capital Management Inc. bought a new stake in shares of Agilent Technologies in the 4th quarter valued at $28,000. Finally, Keating Financial Advisory Services Inc. acquired a new stake in Agilent Technologies during the 2nd quarter worth $31,000. Institutional investors and hedge funds own 87.41% of the company’s stock.
Agilent Technologies Company Profile (Get Free Report)
Agilent Technologies, Inc is an analytical measurement and laboratory technology company serving the life sciences, diagnostics, pharmaceutical, chemical, environmental, food, energy and academic research markets. Its solutions help laboratories analyze the composition, quality and performance of materials, biological samples and other substances.
The company’s products and services include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy equipment, laboratory automation tools, software, consumables and supplies.
Further Reading Five stocks we like better than Agilent Technologies CarMax Just Gave Investors a Better Reason to Believe in the Turnaround CoreWeave Comes With Risks: Analysts Split on What Matters Most Bottlenecking the Future: TSMC Prices Out the Competition Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock? Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
Agilent Technologies má od 20 sledovaných analytiků průměrné doporučení na úrovni „Moderate Buy“ a cílovou cenu 170,33 USD. Firma zároveň za poslední čtvrtletí vykázala EPS 1,62 USD při tržbách 1,88 miliardy USD.
Shares of Agilent Technologies, Inc. (NYSE:A – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the twenty research firms that are covering the stock, MarketBeat reports. Five analysts have rated the stock with a hold recommendation, fourteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $170.33.
Several analysts have issued reports on A shares. Weiss Ratings upgraded Agilent Technologies from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, September 11th. Stifel Nicolaus lifted their target price on Agilent Technologies from $170.00 to $180.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. Jefferies Financial Group assumed coverage on Agilent Technologies in a report on Thursday, July 9th. They issued a “hold” rating and a $135.00 price target for the company. Piper Sandler assumed coverage on Agilent Technologies in a research report on Thursday, June 11th. They set a “neutral” rating and a $150.00 price target on the stock. Finally, Bank of America raised their price objective on Agilent Technologies from $155.00 to $180.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th.
Check Out Our Latest Stock Analysis on Agilent Technologies
Agilent Technologies Trading Down 0.1% NYSE A opened at $172.60 on Friday. The company has a market capitalization of $48.66 billion, a price-to-earnings ratio of 33.98, a price-to-earnings-growth ratio of 2.63 and a beta of 1.24. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.05 and a quick ratio of 1.56. Agilent Technologies has a 12 month low of $108.35 and a 12 month high of $174.77. The company’s fifty day moving average price is $149.16 and its two-hundred day moving average price is $131.40. Agilent Technologies (NYSE:A – Get Free Report) last released its earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.13. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. The company had revenue of $1.88 billion during the quarter, compared to the consensus estimate of $1.84 billion. During the same quarter in the previous year, the firm earned $1.37 EPS. The company’s revenue was up 8.1% on a year-over-year basis. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. As a group, research analysts predict that Agilent Technologies will post 6.2 earnings per share for the current fiscal year.
Agilent Technologies Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 28th. Shareholders of record on Tuesday, October 6th will be issued a dividend of $0.2550 per share. This represents a $1.02 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Tuesday, October 6th. Agilent Technologies’s dividend payout ratio is 20.08%.
Insider Activity In other news, Director Mikael Dolsten sold 634 shares of Agilent Technologies stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $151.38, for a total value of $95,974.92. Following the completion of the transaction, the director directly owned 4,924 shares of the company’s stock, valued at approximately $745,395.12. The trade was a 11.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Hedge Funds Weigh In On Agilent Technologies Large investors have recently bought and sold shares of the business. Greenleaf Trust grew its holdings in shares of Agilent Technologies by 0.8% in the 2nd quarter. Greenleaf Trust now owns 8,117 shares of the medical research company’s stock worth $1,078,000 after acquiring an additional 68 shares during the last quarter. Nilsine Partners LLC raised its position in shares of Agilent Technologies by 0.8% during the second quarter. Nilsine Partners LLC now owns 9,650 shares of the medical research company’s stock worth $1,282,000 after purchasing an additional 72 shares during the period. Sapient Capital LLC lifted its holdings in shares of Agilent Technologies by 4.2% during the first quarter. Sapient Capital LLC now owns 2,105 shares of the medical research company’s stock valued at $240,000 after purchasing an additional 85 shares during the last quarter. Integrated Wealth Concepts LLC lifted its holdings in shares of Agilent Technologies by 0.8% during the second quarter. Integrated Wealth Concepts LLC now owns 11,555 shares of the medical research company’s stock valued at $1,535,000 after purchasing an additional 88 shares during the last quarter. Finally, UNIVEST FINANCIAL Corp boosted its position in shares of Agilent Technologies by 1.3% in the 2nd quarter. UNIVEST FINANCIAL Corp now owns 7,145 shares of the medical research company’s stock valued at $949,000 after purchasing an additional 93 shares during the period.
Agilent Technologies Company Profile (Get Free Report)
Agilent Technologies, Inc is a global provider of analytical instruments, laboratory software, consumables and services used by organizations in the life sciences, diagnostics, pharmaceutical, chemical, environmental and food industries. Its solutions help customers analyze the composition and quality of substances, develop and manufacture products, and conduct research and testing.
The company’s offerings include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy and atomic analysis equipment, automated electrophoresis systems, laboratory informatics software, columns and other consumables.
Further Reading Five stocks we like better than Agilent Technologies Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
Agilent za poslední měsíc přidal asi 9,6 % po silných výsledcích za 3. fiskální čtvrtletí 2026, kdy zisk i tržby překonaly odhady. Firma zároveň zvýšila výhled tržeb i zisku na celý fiskální rok 2026.
It has been about a month since the last earnings report for Agilent Technologies (A - Free Report) . Shares have added about 9.6% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Agilent due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.
Agilent Q3 Earnings Beat Estimates on Pharma and China StrengthAgilent Technologies reported third-quarter fiscal 2026 non-GAAP earnings of $1.62 per share, up 18% year over year and beating the Zacks Consensus Estimate by 9.46%.
Revenues of $1.88 billion rose 8.1% on a reported basis and 7.3% on a core basis, surpassing the consensus mark by 2.08%.
Strength reflected broad demand across pharma and China, while the Advanced Therapeutics Division grew nearly 30%. Instrument book-to-bill remained above 1.0 for the 10th consecutive quarter, underscoring healthy equipment demand.
A's Q3 Segment PerformanceLife Sciences and Diagnostics Markets Group revenues were $746 million, up 11% on a reported basis and 10% on a core basis. The segment's operating margin expanded to 23.5% from 17.6% a year ago, aided by strong liquid chromatography demand. Biocare contributed $10 million after the acquisition closed in late June.
Agilent CrossLab Group revenues increased 6% to $786 million on a reported basis and 5% on a core basis. Its operating margin rose 100 basis points to 34.3%.
Applied Markets Group revenues climbed 7% to $346 million on both reported and core bases, while operating margin increased 310 basis points to 24.9%. CrossLab services grew at a mid-single-digit rate, while consumables increased at a high-single-digit pace across all regions.
Agilent's End-Market MomentumPharmaceutical and biotechnology revenues were $707 million on a GAAP basis. GLP-1-related revenues increased more than 70%, while pharma growth excluding the CDMO business was 9%.
Diagnostics and clinical core revenues rose 6%, supported by mid-teens companion diagnostics growth, high-single-digit genomics growth and double-digit pathology orders.
Chemicals and advanced materials core revenues grew 7%, driven by semiconductor demand, while environmental and forensics rose 5%. Food was flat, and academia and government declined 3%. New-product traction was also notable, with the 9500 Triple Quad ICP-MS order funnel exceeding $60 million and initial orders for the new flagship GC systems running at more than twice expectations.
A's Margin and Expense TrendsNon-GAAP gross margin expanded to 56.4% from 53.1% a year earlier. The quarter included about 160 basis points of benefit from tariff refunds. Excluding that benefit, gross margin was 54.9%, up 180 basis points year over year.
Research and development (R&D) expenses on a non-GAAP basis were $118 million, up 7.3% from the prior-year quarter. Selling, general and administrative (SG&A) expenses on a non-GAAP basis rose to $410 million, marking a 9.3% increase from the prior-year quarter.
Non-GAAP operating margin improved 320 basis points to 28.3%, including about 110 basis points from tariff refunds. Excluding refunds, operating margin was 27.2%, up 210 basis points.
Agilent's Cash Flow and Balance SheetCash and cash equivalents were $1.76 billion as of July 31, 2026, compared with $1.79 billion as of Oct. 31, 2025.
Long-term debt increased to $3.65 billion from $3.05 billion.
Operating cash flow was $519 million in the quarter. Free cash flow was $439 million, representing a 96% conversion of non-GAAP net income.
In the third quarter of fiscal 2026, Agilent repurchased $78 million of shares and paid $72 million in dividends.
A's Q4 and Fiscal 2026 OutlookFor the fourth quarter of fiscal 2026, Agilent expects revenues of $1.98-$2.00 billion, implying reported growth of 6.4-7.4% and core growth of 5.2-6.2%. Non-GAAP earnings are projected to be in the range of $1.71-$1.74 per share. The outlook includes about $23 million of Biocare revenues and no future benefit from potential tariff refunds.
For fiscal 2026, revenues are now projected to be between $7.49 and $7.51 billion, representing reported growth of 7.8-8.1% and core growth of 5.8-6.0%. Non-GAAP earnings are expected to be $6.18-$6.21 per share, up 15 cents at the midpoint from the prior guide. Non-GAAP operating margin expansion is expected to exceed 130 basis points, including about 30 basis points from third-quarter tariff refunds. Operating cash flow is expected to be $1.6-$1.7 billion, with capital expenditures of about $450 million.
How Have Estimates Been Moving Since Then?It turns out, fresh estimates have trended upward during the past month.
VGM ScoresCurrently, Agilent has a average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. Following the exact same course, the stock has a score of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Agilent has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Agilent Technologies uvedla, že růst táhnou Čína, zlepšující se koncové trhy, zisky podílů na trhu, obměna přístrojů a automatizace laboratoří; růst tržeb se zhruba z nuly před dvěma lety zrychlil na téměř 10 % až 11 %.
AutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryAgilent Technologies NYSE: A executives outlined continued growth momentum, driven by improving end markets, market-share gains, instrument replacement cycles and operational changes under the company’s Ignite transformation program, during a J.P. Morgan conference discussion.
Chief Executive Officer Padraig McDonnell said Ignite has evolved from a transformation initiative into an operating system for resource allocation, operations and innovation. He said Agilent’s growth has improved from roughly flat two years ago to nearly 10% to 11%, while operating margin expanded by more than 100 basis points despite tariff headwinds. Earnings per share, which declined 3% two years ago, grew 6% in 2025 and is now growing 10%, he said.
Get Agilent Technologies alerts:
China, replacement cycles support growth 3 Surging Stocks That Don’t Need the AI Boom to Keep WinningMcDonnell said China delivered broad-based strength in the fiscal third quarter, including double-digit growth in pharma and food and high-teens growth in advanced materials. The company attributed the performance both to improving conditions and to its long-standing direct presence in China, including local manufacturing, technical teams and a sizable installed base.
Although Agilent is not calling an inflection point in China, McDonnell said it expects the country to be a mid- to high-single-digit long-term growth market. He pointed to investment in pharmaceuticals, chemicals, advanced materials, semiconductors, batteries, food and environmental testing. The company recently opened an innovation center in China focused on physical automation, he said.
Gold Has Gone Sideways, But These 3 Stocks Haven’tManagement also highlighted ongoing replacement cycles in liquid chromatography, or LC, and gas chromatography, or GC. McDonnell said LC posted double-digit growth during the latest quarter and that Agilent is less than halfway through its LC replacement cycle, which the company estimates could add 200 to 300 basis points to the overall business. China represents one area where fleets are older and replacements could accelerate, he added.
Agilent estimates it is about one-quarter through its GC replacement cycle, which McDonnell said could contribute roughly 100 basis points of growth to the overall business. The company sees opportunities across chemical and energy customers, food and environmental testing, semiconductor fabs and suppliers of high-purity chemicals.
Automation and scientific intelligence McDonnell said Agilent is concentrating investment on autonomous laboratories and scientific intelligence, with artificial intelligence serving as a key enabler. He described analytical tools as the “eyes” of a laboratory, physical automation as the “hands,” and an agentic layer as the “brain” directing experiments.
According to McDonnell, AI could expand demand for testing and drug-release work as pharmaceutical customers seek to shorten clinical-trial timelines and develop more molecules. Agilent has established an autonomous lab group under Chief Technology Officer August Specht that works alongside the company’s AI organization. Management said it expects future opportunities in automation-ready instruments, physical automation, software and partnerships, as well as selective acquisitions.
Advanced therapeutics expansion remains on track Agilent’s advanced therapeutics specialty CDMO business grew 30% in the fiscal third quarter, in line with company expectations. Management expects growth to be flat in the fourth quarter due to regulatory filing timing and a comparison with growth above 40% in the prior year. Over the long term, the company expects mid-teens growth for the business.
Chief Financial Officer Adam Elinoff said Train C is expected to begin operations in spring 2027 and is 75% booked for next year. Train C is expected to take six to eight quarters to reach full capacity, while Train D is expected to come online a couple of quarters later and require another six to eight quarters to ramp. At full capacity, the two trains could roughly double revenue from the site to about $300 million, he said.
Elinoff said the CDMO customer base has become more diversified. In 2019, three customers represented 80% of demand; now, three customers account for less than 50%. In 2025, the business was 60% commercial and 40% clinical, with commercial activity increasing. Management said recent clinical-trial news had not affected its 2027 forecast and reiterated confidence in the siRNA market.
Train C’s ramp will be dilutive to margins in 2027 because of hiring and depreciation ahead of full utilization, Elinoff said. However, he said Agilent remains committed to delivering 50 to 100 basis points or more of long-term annual operating-margin expansion through Ignite-related efficiencies.
Reshoring orders and capital allocation McDonnell said Agilent has begun booking its first reshoring and onshoring orders, with five of the top 10 pharmaceutical companies placing orders. The company continues to see a $300 million opportunity from reshoring by 2030, representing about one-third of an estimated $1 billion market opportunity. Most orders so far have come from greenfield sites, with procurement generally occurring six to 18 months before a site launch, he said.
Management expects reshoring benefits to begin appearing in the first fiscal quarter and beyond. The opportunity spans LC, GC, spectroscopy, services and consumables, according to McDonnell.
On capital allocation, executives said they intend to prioritize internal innovation, strategic capacity investments and disciplined acquisitions. McDonnell cited Biocare as an example of an acquisition that expands recurring revenue and strengthens Agilent’s pathology franchise. He said the company would not pursue a transformative deal, instead focusing on targeted additions that fill technology gaps, add recurring revenue or software capabilities, and support the company’s analytical and autonomous-laboratory strategy.
About Agilent Technologies (NYSE:A)Agilent Technologies, Inc is a global provider of analytical instruments, laboratory software, consumables and services used by organizations in the life sciences, diagnostics, pharmaceutical, chemical, environmental and food industries. Its solutions help customers analyze the composition and quality of substances, develop and manufacture products, and conduct research and testing.
The company's offerings include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy and atomic analysis equipment, automated electrophoresis systems, laboratory informatics software, columns and other consumables.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Agilent Technologies Right Now?Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Bank of America Corp DE ve 2. čtvrtletí koupila nový podíl ve společnosti Agilent Technologies za zhruba 213,269 milionu USD. Získala 1 605 576 akcií, asi 0,57 % firmy.
Bank of America Corp DE purchased a new stake in Agilent Technologies, Inc. (NYSE:A – Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund purchased 1,605,576 shares of the medical research company’s stock, valued at approximately $213,269,000. Bank of America Corp DE owned about 0.57% of Agilent Technologies as of its most recent filing with the SEC.
Other large investors also recently made changes to their positions in the company. Norges Bank purchased a new stake in Agilent Technologies in the fourth quarter valued at approximately $549,158,000. Bank of New York Mellon Corp grew its stake in shares of Agilent Technologies by 87.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company’s stock valued at $695,227,000 after buying an additional 2,440,360 shares during the period. Legal & General Group Plc purchased a new stake in shares of Agilent Technologies during the 2nd quarter valued at $260,101,000. Man Group plc acquired a new stake in shares of Agilent Technologies during the 2nd quarter worth $179,257,000. Finally, Primecap Management Co. CA acquired a new stake in shares of Agilent Technologies during the 2nd quarter worth $176,318,000.
Agilent Technologies Stock Up 2.1% Shares of NYSE:A opened at $153.46 on Thursday. The company has a market capitalization of $43.26 billion, a price-to-earnings ratio of 30.21, a price-to-earnings-growth ratio of 2.29 and a beta of 1.24. The company has a 50 day moving average of $144.90 and a two-hundred day moving average of $129.22. Agilent Technologies, Inc. has a 52-week low of $108.35 and a 52-week high of $163.75. The company has a quick ratio of 1.56, a current ratio of 2.05 and a debt-to-equity ratio of 0.50.
Agilent Technologies (NYSE:A – Get Free Report) last posted its earnings results on Wednesday, August 26th. The medical research company reported $1.62 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.13. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. The business had revenue of $1.88 billion for the quarter, compared to analysts’ expectations of $1.84 billion. During the same period in the previous year, the company posted $1.37 earnings per share. The business’s revenue for the quarter was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. As a group, analysts forecast that Agilent Technologies, Inc. will post 6.2 earnings per share for the current fiscal year. Agilent Technologies Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 28th. Investors of record on Tuesday, October 6th will be paid a $0.255 dividend. The ex-dividend date is Tuesday, October 6th. This represents a $1.02 annualized dividend and a dividend yield of 0.7%. Agilent Technologies’s payout ratio is 20.08%.
Analyst Ratings Changes A number of brokerages recently weighed in on A. TD Cowen lifted their target price on Agilent Technologies from $155.00 to $180.00 and gave the company a “buy” rating in a report on Thursday, August 27th. Sanford C. Bernstein upped their price target on Agilent Technologies from $155.00 to $180.00 and gave the stock an “outperform” rating in a research note on Thursday, August 27th. Bank of America raised their price objective on Agilent Technologies from $155.00 to $180.00 and gave the stock a “buy” rating in a report on Thursday, August 27th. Wells Fargo & Company reduced their price objective on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. Finally, Jefferies Financial Group started coverage on Agilent Technologies in a report on Thursday, July 9th. They set a “hold” rating and a $135.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $170.33.
Read Our Latest Analysis on Agilent Technologies
Insider Buying and Selling In other Agilent Technologies news, Director Mikael Dolsten sold 634 shares of Agilent Technologies stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $151.38, for a total transaction of $95,974.92. Following the sale, the director directly owned 4,924 shares in the company, valued at $745,395.12. The trade was a 11.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Agilent Technologies Profile (Free Report)
Agilent Technologies, Inc is a global provider of analytical instruments, laboratory software, consumables and services used by organizations in the life sciences, diagnostics, pharmaceutical, chemical, environmental and food industries. Its solutions help customers analyze the composition and quality of substances, develop and manufacture products, and conduct research and testing.
The company’s offerings include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy and atomic analysis equipment, automated electrophoresis systems, laboratory informatics software, columns and other consumables.
Featured Articles Five stocks we like better than Agilent Technologies 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector Jackson’s Record Quarter Powers the Bull Case Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
Agilent Technologies zvýšila celoroční odhad upraveného zisku na 6,18 až 6,21 USD na akcii díky lepší poptávce po laboratorních a lékařských přístrojích. Tržby za třetí čtvrtletí vzrostly na 1,88 miliardy USD a překonaly odhad.
Agilent Technologies (A.N) raised its annual profit forecast on Wednesday, betting on improving demand for its medical tools and equipment used in lab research and drug development.
Demand conditions are improving for U.S. life sciences and laboratory-equipment companies after a prolonged downturn driven by constrained biotech funding and uneven demand.
Agilent now expects an annual adjusted profit of $6.18 to $6.21 per share, compared to its previous forecast of $6 to $6.10 apiece.
"We are seeing improving end markets, stronger demand in key regions, and excellent customer response to our innovative product launches," CEO Padraig McDonnell said.
Analysts, on average, were expecting revenue of $7.45 billion and an adjusted profit of $6.06 per share for the year, according to data compiled by LSEG.
The company's third-quarter revenue rose to $1.88 billion, topping analysts' estimate of $1.84 billion.
Its adjusted profit for the quarter ended July 31 was $1.62 per share, including a 6-cent benefit from tariff refunds, compared with an estimated $1.49 per share.
Revenue from its CrossLab unit, which offers products and services for laboratory management, rose 6% to $786 million in the quarter.
Agilent Technologies (A - Free Report) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.48 per share. This compares to earnings of $1.37 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +9.46%. A quarter ago, it was expected that this scientific instrument maker would post earnings of $1.4 per share when it actually produced earnings of $1.49, delivering a surprise of +6.43%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Agilent, which belongs to the Zacks Medical - Products industry, posted revenues of $1.88 billion for the quarter ended July 2026, surpassing the Zacks Consensus Estimate by 2.08%. This compares to year-ago revenues of $1.74 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Agilent shares have added about 13.7% since the beginning of the year versus the S&P 500's gain of 12.2%.
What's Next for Agilent?While Agilent has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Agilent was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.71 on $1.97 billion in revenues for the coming quarter and $6.05 on $7.45 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the top 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Medtronic (MDT - Free Report) , is yet to report results for the quarter ended July 2026. The results are expected to be released on September 1.
This medical device company is expected to post quarterly earnings of $1.39 per share in its upcoming report, which represents a year-over-year change of +10.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Medtronic's revenues are expected to be $9.47 billion, up 10.4% from the year-ago quarter.
Agilent Technologies zveřejnila výsledky za 3. čtvrtletí fiskálního roku 2026. V konferenčním hovoru vedení uvedlo, že komentáře se budou vztahovat i na ne-GAAP finanční ukazatele.
Agilent Technologies, Inc. (A) Q3 2026 Earnings Call August 26, 2026 4:30 PM EDT
Company Participants
Tejas Savant - Vice President of Investor Relations
Padraig McDonnell - CEO, President & Director
Adam Elinoff - Senior VP, CFO & Principal Financial Officer
Simon May - Senior VP and President of Life Sciences & Diagnostics Markets Group
Angelica Riemann - Senior VP & President of Agilent CrossLab Group
Conference Call Participants
Jack Meehan - Operon Research, LLC
Vijay Kumar - Evercore ISI Institutional Equities, Research Division
Tycho Peterson - Jefferies LLC, Research Division
Michael Ryskin - BofA Securities, Research Division
Dan Leonard - RBC Capital Markets, Research Division
Puneet Souda - Leerink Partners LLC, Research Division
Daniel Brennan - TD Cowen, Research Division
Kallum Titchmarsh - Morgan Stanley, Research Division
Elizabeth Koslosky - Goldman Sachs Group, Inc., Research Division
Casey Woodring - JPMorgan Chase & Co, Research Division
Presentation
Operator
Ladies and gentlemen, thank you for joining us, and welcome to the Q3 2026 Agilent Technologies, Inc. Earnings Conference Call. [Operator Instructions]
I will now hand the call over to Tejas Savant, Head of Investor Relations. You may begin.
Tejas Savant
Vice President of Investor Relations
Thank you, and welcome, everyone, to Agilent's conference call for the third quarter of fiscal year 2026. With me on the line are CEO, Padraig McDonnell; and CFO, Adam Elinoff. Joining for the Q&A will be Simon May, President of the Life Sciences and Diagnostics Markets Group; Angelica Riemann, President of the Agilent CrossLab Group; and Mike Zhang, President of the Applied Markets Group.
This presentation is being webcast live. The press release for our third quarter financial results, investor presentation and information to supplement today's discussion, along with the recording of this webcast, are available on our website at investor.agilent.com.
Today's comments will refer to non-GAAP financial measures. Non-GAAP measures are supplemental and should not be considered
Agilent Technologies oznámí výsledky za 3. čtvrtletí fiskálního roku 2026 po uzavření trhu 26. srpna po zvýšení celoročního výhledu. Ve 2. čtvrtletí tržby vzrostly na 1,835 mld. USD a non-GAAP EPS činil 1,49 USD.
Agilent Technologies (NYSE:A | A Price Prediction) heads into a pivotal earnings setup for retirement-oriented portfolios, with a company-confirmed Q3 2026 report after the close on Aug. 26 arriving on top of a raised guide, expanding margins, and a fresh product cycle that management already said Ignite pulled forward by a full quarter. Every operating lever is pointing the same direction, leaving little room for a coin-flip outcome.
Beat-and-Raise Momentum Is Already Compounding Agilent walked out of Q2 with revenue of $1.835 billion, up 10.01% year over year, non-GAAP EPS of $1.49 versus a $1.4083 estimate (a 5.8% surprise), and non-GAAP operating margin of 26.4%, up 130 basis points. Net income jumped 57.67%. Management then raised the full year to $7.39B–$7.49 billion in revenue and $6 to$6.10 in EPS. The Q3 guide of $1.83 billion to $1.85 billion in revenue and $1.48–$1.50 EPS is the number to clear, and the last beat produced a 16.87 day-of-change.
Catalyst Stack: 9500 ICP-MS, Replacement Cycle, Ignite The 9500 triple quad ICP-MS launch was expedited by a full quarter via Ignite, and Agilent has now printed a book-to-bill above one for nine consecutive quarters. Instrument revenue grew high single digits with LC, LC-MS, and GC in the low double digits. Pricing delivered roughly 200 basis points in Q2, double the original full-year goal. This is a durable margin story into a live replacement cycle.
Valuation and the Head-to-Head Agilent trades at a forward P/E of 22 with an analyst target of $160.11 and 17 Buy or Strong Buy ratings against zero Sell ratings. Compare that to Waters Corporation (NYSE:WAT), which is still digesting the BD Biosciences deal. Waters posted a Q2 net loss of $136 million against $232 million of intangible amortization and $155 million of inventory step-up charges, with organic constant-currency growth of 9%. Against Thermo Fisher Scientific (NYSE:TMO), Agilent’s 26.4% operating margin beats Thermo’s 22.8% adjusted operating margin, and Agilent grew reported revenue faster in Q2 (10.01% versus Thermo’s 10.49% with far less acquisition help). Cleaner P&L, better margin, same growth.
Only Real Risk, Dismissed Bears point to the Q1 FY2026 miss (EPS $1.36 versus $1.3683), but management tied it to a U.S. snowstorm in the final week and still raised full-year guidance. Q2 answered with a clean beat and another raise. The stock is now up more than 22% in one month and 33.5% over the past year, and it still sits below the $160.11 analyst target.
Keep an eye on the stock into the August 26 close.
Contact [email protected] for any questions or corrections.
Agilent rozšiřuje AI software a automatizaci pro biopharmaceutický růst a spouští xCELLigence RTCA eSight AI pro analýzu živých buněk. Ve 3. fiskálním čtvrtletí čeká tržby 1,83–1,85 mld. USD.
Key Takeaways Agilent is expanding its AI software and automation portfolio to support its biopharma growth prospects. Agilent launched xCELLigence RTCA eSight AI to simplify label-free live-cell imaging analysis. A expects fiscal Q3 2026 revenues of $1.83B-$1.85B, implying 5.0%-6.5% reported growth. Agilent Technologies (A - Free Report) shares have lost 5.2% in the year-to-date period, underperforming the Zacks Medical industry's 2.8% growth. The dip reflects cautious laboratory spending and a challenging macroeconomic environment.
However, Agilent continues to strengthen its long-term growth prospects through product innovation and expanding artificial intelligence (AI)-enabled laboratory software and automation capabilities, supported by healthy demand across the pharmaceutical, diagnostics and advanced materials markets.
The company also benefits from growing demand for AI-enabled laboratory software and automation as pharmaceutical and biotechnology companies increasingly digitize research workflows and accelerate drug discovery. Agilent's integrated software ecosystem, led by its OpenLab and xCELLigence platforms, combines analytical instruments, software and laboratory automation to improve productivity, reduce manual intervention and deliver more consistent scientific results.
Agilent Expands AI-Powered Cell Analysis PortfolioAgilent continues to strengthen its AI-enabled laboratory portfolio through innovations spanning analytical instruments, laboratory software, automation and digital workflows, supporting the growing adoption of AI-driven research solutions.
Building on this strategy, the company launched xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free live-cell imaging analysis. The software enhances the xCELLigence RTCA eSight platform by combining AI-driven image analysis with impedance measurements, enabling researchers to analyze imaging and cell behavior simultaneously from the same experiment.
The new module replaces manual cell segmentation and subjective parameter tuning with a one-click automated workflow, helping researchers generate more consistent and reproducible results while reducing analysis time and lowering training requirements. Designed for drug discovery and high-throughput biopharma research, the software is expected to accelerate scientific workflows, improve laboratory productivity and expand adoption of Agilent's integrated cell analysis platform, supporting long-term software and biopharma growth.
AI Innovation Strengthens Agilent's Growth StoryAgilent continues to expand its AI capabilities across laboratory software, automation and digital workflows. During the second quarter of fiscal 2026, AI was highlighted as a key long-term growth driver, with increasing customer adoption and continued investments in digital laboratory solutions expected to support sustainable growth. Agilent is integrating AI across its analytical instruments, laboratory informatics and automation solutions to enhance scientific workflows and operational efficiency.
Agilent is further expanding its digital laboratory capabilities through its announcement of the China Innovation Center in June 2026, which focuses on AI, automation and digital laboratory technologies to enable next-generation smart laboratories. These initiatives strengthen Agilent's AI-enabled laboratory portfolio and are expected to address growing demand for AI-powered laboratory software and automation solutions, strengthening the company's long-term growth prospects.
Agilent Provides Strong Fiscal Q3 2026 OutlookAgilent's improving demand environment, expanding AI software portfolio and continued product innovation are expected to benefit the company’s top-line growth.
For the third quarter of fiscal 2026, A expects revenues to be in the range of $1.83-$1.85 billion, implying 5.0%-6.5% reported growth and 4.4%-5.9% core growth.
The Zacks Consensus Estimate for third-quarter fiscal 2026 revenues is pegged at $1.84 billion, indicating year-over-year growth of approximately 6.02%.
The consensus estimate for third-quarter fiscal 2026 earnings is pegged at $1.47 per share, which has decreased by a penny over the past 30 days, indicating year-over-year growth of 7.30%.
A’s Zacks Rank & Stocks to ConsiderCurrently, Agilent carries a Zacks Rank #3 (Hold).
Fortrea Holdings Inc (FTRE - Free Report) , Neurocrine Biosciences (NBIX - Free Report) and PTC Therapeutics (PTCT - Free Report) are some better-ranked stocks that investors can consider in the broader Zacks Medical sector. Fortrea Holdings Inc, Neurocrine Biosciences and PTC Therapeutics sport a Zacks Rank #1 (Strong Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
FTRE shares have lost 1.4% in the year-to-date period. The long-term earnings growth rate for Fortrea Holdings is pegged at 40.91%.
NBIX shares have risen 25.6% in the year-to-date period. The long-term earnings growth rate for Neurocrine Biosciences is pegged at 33.41%.
Shares of PTCT have gained 16.6% in the year-to-date period. The long-term earnings growth rate for PTC Therapeutics is pegged at 27.74%.
Agilent uvedl AI modul pro xCELLigence RTCA eSight, který zjednodušuje analýzu buněčného zobrazování a snižuje ruční nastavování i variabilitu výsledků. Novinka má urychlit výzkum v biopharmě a objevování léčiv.
Simplifying label-free imaging analysis for more confident real-time cell analysis
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to gain imaging and impedance insights from the same cells in the same experiment with greater speed and confidence. This streamlined, integrated approach is expected to provide biopharma researchers with a more complete view of cell behavior while reducing variability across users and conditions.
"By making advanced AI-powered image analysis accessible to more labs, we're enabling more consistent, reproducible insights that help accelerate discovery and translational research." — Knut Wintergerst, vice president and general manager, Agilent
Share Traditional cell segmentation workflows rely on time-consuming and subjective manual setup and analysis steps that increase variability, error and rework, slowing experimental timelines while also requiring a higher level of experimental expertise to achieve consistent results. As biopharma research increasingly demands more complex experiments, higher throughput and greater consistency, integrated workflows are key to efficient scientific progress. AI-driven imaging analysis can help reduce variability across users while decreasing time spent on manual analysis.
By replacing subjective, user-influenced thresholding and manual parameter tuning with a one-click approach, the new module delivers standardized analysis across skill levels, experiments and datasets. eSight imaging AI analysis is designed to ensure confident, reliable performance across users, cell types and assay conditions, providing the robustness and accuracy essential for real-world science and users with varying levels of imaging expertise.
The new module is expected to reduce time spent on manual analysis, rework and training while supporting broader application of label-free imaging workflows, specifically within drug discovery and in high-throughput biopharma research.
"The AI analysis module for xCELLigence RTCA eSight has substantially reduced the time our users spend for image analysis," said Carole Perrot, Ph.D., core facility director at Johns Hopkins All Children's Hospital. "Its automated, consistent performance across a variety of cell types and experimental conditions has improved workflow efficiency while helping ensure reproducible results. As a shared resource supporting multiple research projects, the xCELLigence is without a doubt one of our best instruments as it simplifies complex analyses and makes advanced imaging more accessible to our users."
Knut Wintergerst, vice president and general manager of the Life Sciences and Diagnostics Markets Group at Agilent, added, "With xCELLigence RTCA eSight Software 1.5.0, Agilent is bringing the same straightforward, objective analysis customers have long valued in impedance-based measurements to label-free live cell imaging. By making advanced AI-powered image analysis accessible to more labs, we’re enabling more consistent, reproducible insights that help accelerate discovery and translational research."
By simplifying label-free imaging analysis within an integrated imaging and impedance workflow, eSight AI helps researchers reduce complexity, gain more confident biological insights and accelerate the path from experiment to interpretation.
About Agilent Technologies
Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
It has been about a month since the last earnings report for Agilent Technologies (A - Free Report) . Shares have added about 0.1% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Agilent due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers.
Agilent Technologies Q2 Earnings Beat Estimates, Revenues Up Y/YAgilent Technologies reported second-quarter fiscal 2026 earnings of $1.49 per share, up 13.7% year over year. The figure surpassed the Zacks Consensus Estimate by 6.21%.
Quarterly revenues came in at $1.84 billion, which represented 10% reported growth year over year. The figure beat the Zacks Consensus Estimate by 2.12%. Strength in instruments and solid execution also supported a favorable mix, with 66% of fiscal second-quarter revenue coming from recurring streams such as consumables, services and informatics.
A Posts Strong Q2 Growth Across Operating SegmentsA’s top-line expansion was broad-based across its three reporting groups. The Life Sciences and Diagnostics Markets Group generated $732 million of revenues, up 12% year over year on a reported basis and 9% on a core basis.
Agilent CrossLab delivered $759 million, reflecting 6% reported growth and 2% core growth, while Applied Markets recorded $344 million, increasing 14% reported and 11% core. Segment profitability remained solid, with operating margins of 22.0% in LDG, 32.0% in CrossLab and 23.3% in Applied Markets.
Agilent’s Q2 Operating ResultsFor the second quarter of fiscal 2026, the LDG segment’s gross margin expanded 130 basis points (bps) year over year to 54.1%. ACG’s gross margin was flat year over year to 55.5%, while AMG’s gross margin expanded 230 bps year over year to 55.8%.
Research and development (R&D) expenses on a non-GAAP basis were $116 million, up 6.4% from the prior-year quarter. Selling, general, and administrative (SG&A) expenses on a non-GAAP basis rose to $409 million, marking a 9.4% increase from the prior-year quarter.
As a percentage of revenues, R&D expenses fell 20 bps year over year to 6.3%, while SG&A expenses fell 10 bps year over year to 22.3%.
Non-GAAP operating margin expanded 130 basis points year over year to 26.4% and improved 180 basis points sequentially.
A Sees Divergent Trends Across End MarketsDemand trends varied by end market, but the overall mix remained constructive. Pharma, which represented 36% of quarterly revenues, delivered 6% core growth and marked a fifth straight quarter of mid-single to low-double-digit growth, including low-double-digit growth in biotech.
Diagnostics and Clinical (16% of revenue) rose 11% on core growth, supported by expansion in Cancer Diagnostics offerings and traction for the Omnis family. Chemicals and Advanced Materials (23% of revenue) increased 8%, driven by semiconductor demand and chemicals capex investments in the Americas, while Environmental and Forensics (10% of revenue) grew 13% on competitive wins and a TSA airport security contract. Offsetting pockets of strength, Academia and Government (7% of revenue) declined 5% amid a muted research funding environment, and Food (8% of revenue) fell 3% on funding delays in China and India.
Agilent Details Geography and Business Mixeographically, results reflected strength in the Americas and Europe and a tougher year-over-year comparison in Asia-Pacific. Core revenue growth was 11% in the Americas and 8% in Europe, while APAC declined 1% on a core basis. In terms of mix, the Americas accounted for 42% of Agilent’s fiscal second-quarter revenue, Europe contributed 28% and APAC represented 30%.
Agilent also highlighted the durability of its model through the product-type mix. Consumables, services and informatics represented 66% of total revenues in the quarter, while instruments accounted for the remaining 34%. The company emphasized robust instrument growth in the quarter alongside an increasing recurring-revenue mix.
A’s Balance Sheet DetailsThe balance sheet remained steady. Cash and cash equivalents totaled $1.807 billion as of April 30, 2026, compared with $1.75 billion as of Jan. 31, 2025, while long-term debt stood at $3.051 billion.
Agilent generated $277 million in operating cash flow during the quarter and returned cash to shareholders through multiple channels. The company spent $65 million to repurchase 0.55 million shares and paid $72 million in dividends, along with $76 million of capex investment.
A Raises Full-Year Outlook and Issues Q3 TargetsA lifted its fiscal 2026 outlook, driven by increased confidence in business performance and execution. Full-year revenues are now expected to be in the range of $7.39-$7.49 billion, with core revenue growth projected to be between 4.5% and 6.0%. The company also expects 85 basis points of non-GAAP operating margin expansion at the midpoint of core growth guidance.
For the third quarter of fiscal 2026, A expects revenues in the range of $1.83-$1.85 billion, implying 5.0%-6.5% reported growth and 4.4%-5.9% core growth. Non-GAAP earnings for the quarter are expected to be in the range of $1.48-$1.50 per share, while full-year non-GAAP earnings were raised to $6.00-$6.10 per share.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates review.
VGM ScoresCurrently, Agilent has a subpar Growth Score of D, a score with the same score on the momentum front. Following the exact same course, the stock was allocated a score of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. Interestingly, Agilent has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
